These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 30295677)

  • 1. Charcot‑Marie‑Tooth type 1A drug therapies: role of adenylyl cyclase activity and G‑protein coupled receptors in disease pathomechanism.
    Kiepura AJ; Kochański A
    Acta Neurobiol Exp (Wars); 2018; 78(3):198-209. PubMed ID: 30295677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy.
    Chumakov I; Milet A; Cholet N; Primas G; Boucard A; Pereira Y; Graudens E; Mandel J; Laffaire J; Foucquier J; Glibert F; Bertrand V; Nave KA; Sereda MW; Vial E; Guedj M; Hajj R; Nabirotchkin S; Cohen D
    Orphanet J Rare Dis; 2014 Dec; 9():201. PubMed ID: 25491744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A).
    Prukop T; Stenzel J; Wernick S; Kungl T; Mroczek M; Adam J; Ewers D; Nabirotchkin S; Nave KA; Hajj R; Cohen D; Sereda MW
    PLoS One; 2019; 14(1):e0209752. PubMed ID: 30650121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A.
    Attarian S; Vallat JM; Magy L; Funalot B; Gonnaud PM; Lacour A; Péréon Y; Dubourg O; Pouget J; Micallef J; Franques J; Lefebvre MN; Ghorab K; Al-Moussawi M; Tiffreau V; Preudhomme M; Magot A; Leclair-Visonneau L; Stojkovic T; Bossi L; Lehert P; Gilbert W; Bertrand V; Mandel J; Milet A; Hajj R; Boudiaf L; Scart-Grès C; Nabirotchkin S; Guedj M; Chumakov I; Cohen D
    Orphanet J Rare Dis; 2014 Dec; 9():199. PubMed ID: 25519680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot-Marie-Tooth disease type 1A (CMT1A) rats.
    Prukop T; Wernick S; Boussicault L; Ewers D; Jäger K; Adam J; Winter L; Quintes S; Linhoff L; Barrantes-Freer A; Bartl M; Czesnik D; Zschüntzsch J; Schmidt J; Primas G; Laffaire J; Rinaudo P; Brureau A; Nabirotchkin S; Schwab MH; Nave KA; Hajj R; Cohen D; Sereda MW
    J Neurosci Res; 2020 Oct; 98(10):1933-1952. PubMed ID: 32588471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A).
    Sereda MW; Meyer zu Hörste G; Suter U; Uzma N; Nave KA
    Nat Med; 2003 Dec; 9(12):1533-7. PubMed ID: 14608378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerability and efficacy study of P2X7 inhibition in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy.
    Sociali G; Visigalli D; Prukop T; Cervellini I; Mannino E; Venturi C; Bruzzone S; Sereda MW; Schenone A
    Neurobiol Dis; 2016 Nov; 95():145-57. PubMed ID: 27431093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A.
    Attarian S; Young P; Brannagan TH; Adams D; Van Damme P; Thomas FP; Casanovas C; Kafaie J; Tard C; Walter MC; Péréon Y; Walk D; Stino A; de Visser M; Verhamme C; Amato A; Carter G; Magy L; Statland JM; Felice K
    Orphanet J Rare Dis; 2021 Oct; 16(1):433. PubMed ID: 34656144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral myelin protein-22 expression in Charcot-Marie-Tooth disease type 1a sural nerve biopsies.
    Hanemann CO; Stoll G; D'Urso D; Fricke W; Martin JJ; Van Broeckhoven C; Mancardi GL; Bartke I; Müller HW
    J Neurosci Res; 1994 Apr; 37(5):654-9. PubMed ID: 8028042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impairment of PMP22 transgenic Schwann cells differentiation in culture: implications for Charcot-Marie-Tooth type 1A disease.
    Nobbio L; Vigo T; Abbruzzese M; Levi G; Brancolini C; Mantero S; Grandis M; Benedetti L; Mancardi G; Schenone A
    Neurobiol Dis; 2004 Jun; 16(1):263-73. PubMed ID: 15207283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy.
    Meyer zu Horste G; Prukop T; Liebetanz D; Mobius W; Nave KA; Sereda MW
    Ann Neurol; 2007 Jan; 61(1):61-72. PubMed ID: 17262851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Many facets of the peripheral myelin protein PMP22 in myelination and disease.
    Naef R; Suter U
    Microsc Res Tech; 1998 Jun; 41(5):359-71. PubMed ID: 9672419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Therapies for Hereditary Peripheral Neuropathies: Systematic Review and Steps Towards a 'treatabolome'.
    Jennings MJ; Lochmüller A; Atalaia A; Horvath R
    J Neuromuscul Dis; 2021; 8(3):383-400. PubMed ID: 32773395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical implications of peripheral myelin protein 22 for nerve compression and neural regeneration: a review.
    Hui-Chou HG; Hashemi SS; Hoke A; Dellon AL
    J Reconstr Microsurg; 2011 Jan; 27(1):67-74. PubMed ID: 20976668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proliferation of Schwann cells and regulation of cyclin D1 expression in an animal model of Charcot-Marie-Tooth disease type 1A.
    Atanasoski S; Scherer SS; Nave KA; Suter U
    J Neurosci Res; 2002 Feb; 67(4):443-9. PubMed ID: 11835311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Study of molecular mechanisms of the relaxin action on adenylyl cyclase signaling system using synthetic peptides derived from the relaxin receptor LGR7].
    Shpakov AO; Gur'ianov IA; Kuznetsova LA; Plesneva SA; Shpakova EA; Vlasov GP; Pertsev MN
    Ross Fiziol Zh Im I M Sechenova; 2006 May; 92(5):521-35. PubMed ID: 16869281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation analysis of PMP22 in Slovak patients with Charcot-Marie-Tooth disease and hereditary neuropathy with liability to pressure palsies.
    Resko P; Radvansky J; Odnogova Z; Baldovic M; Minarik G; Polakova H; Palffy R; Kadasi L
    Gen Physiol Biophys; 2011 Dec; 30(4):379-88. PubMed ID: 22131320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid detection of duplication/deletion of the PMP22 gene in patients with Charcot-Marie-Tooth disease Type 1A and hereditary neuropathy with liability to pressure palsy by real-time quantitative PCR using SYBR Green I dye.
    Kim SW; Lee KS; Jin HS; Lee TM; Koo SK; Lee YJ; Jung SC
    J Korean Med Sci; 2003 Oct; 18(5):727-32. PubMed ID: 14555828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of real-time quantitative PCR compare to repeat PCR for the diagnosis of Charcot-Marie-Tooth Type 1A and hereditary neuropathy with liability to pressure palsies.
    Choi JR; Lee WH; Sunwoo IN; Lee EK; Lee CH; Lim JB
    Yonsei Med J; 2005 Jun; 46(3):347-52. PubMed ID: 15988805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The alpha-chemokine CXCL14 is up-regulated in the sciatic nerve of a mouse model of Charcot-Marie-Tooth disease type 1A and alters myelin gene expression in cultured Schwann cells.
    Barbaria EM; Kohl B; Buhren BA; Hasenpusch-Theil K; Kruse F; Küry P; Martini R; Müller HW
    Neurobiol Dis; 2009 Mar; 33(3):448-58. PubMed ID: 19111616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.